PUMD Stock Overview
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ProUroCare Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -96.55% |
| 5 Year Change | -97.14% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PUMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | -3.5% |
| 1Y | n/a | 2.2% | 20.2% |
Return vs Industry: Insufficient data to determine how PUMD performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how PUMD performed against the US Market.
Price Volatility
| PUMD volatility | |
|---|---|
| PUMD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PUMD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PUMD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Stan Myrum | www.prourocare.com |
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System.
ProUroCare Medical Inc. Fundamentals Summary
| PUMD fundamental statistics | |
|---|---|
| Market cap | US$1.86k |
| Earnings (TTM) | -US$2.11m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PUMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PUMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.11m |
| Earnings | -US$2.11m |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PUMD perform over the long term?
See historical performance and comparison